Читать книгу Assisted Reproduction Techniques - Группа авторов - Страница 176

Breast cancer is the most frequently occurring cancer in women, with an incidence in the UK of 1 in 9 women, of which 15% occur in women under the age of 40 years. The survival rate is around 85%. [1]. Hodgkin’s lymphoma (HL), which demonstrates a peak incidence in the young adult population, is now associated with an overall survival rate of 90% [2,3]. Chemotherapy has a central role in the management of both these and most other cancers. But it is associated with a risk of infertility after completion of treatment. With improved long‐term survival, there has been a shift in focus to quality of life issues of which fertility is a major concern for the patient. Onco‐fertility counseling now should be an integral part of multidisciplinary cancer management but can be challenging in the absence of comprehensive information about the gonadotoxicity of specific drug regimens currently administered. Fertility after chemotherapy is also influenced by other factors such as age and ovarian reserve, making it difficult to accurately predict the risk of infertility after treatment. Discussion about fertility prognosis at diagnosis and provision of fertility preservation is improving, but timely follow‐up after completion of cancer therapy to advise about future fertility and early detection of ovarian insufficiency could be improved.